Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 37.03M | 36.50M | 26.82M | 14.24M | 0.00 | 203.20M |
Gross Profit | 30.82M | 32.33M | 17.32M | 12.54M | -18.78M | 200.39M |
EBITDA | -437.33M | -425.74M | -384.86M | -380.48M | -337.73M | -326.13M |
Net Income | 665.99M | 673.73M | -352.09M | -74.56M | 1.60B | -335.22M |
Balance Sheet | ||||||
Total Assets | 1.56B | 1.66B | 937.12M | 1.24B | 1.44B | 852.95M |
Cash, Cash Equivalents and Short-Term Investments | 893.38M | 893.71M | 776.93M | 1.10B | 1.29B | 670.54M |
Total Debt | 52.94M | 56.99M | 72.00M | 85.66M | 97.09M | 105.20M |
Total Liabilities | 88.99M | 122.24M | 126.10M | 137.90M | 145.76M | 453.45M |
Stockholders Equity | 1.47B | 1.54B | 811.02M | 1.10B | 1.29B | 399.50M |
Cash Flow | ||||||
Free Cash Flow | -403.77M | -391.53M | -297.06M | -314.36M | -413.06M | -305.67M |
Operating Cash Flow | -401.46M | -389.84M | -296.06M | -309.48M | -407.32M | -290.76M |
Investing Cash Flow | 351.47M | 363.44M | 239.57M | 243.26M | 1.25B | 75.75M |
Financing Cash Flow | 10.20M | 14.44M | 5.43M | 2.35M | -765.77M | 261.52M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $1.85B | 12.26 | 24.71% | ― | 20.62% | 14.08% | |
62 Neutral | $2.09B | 3.20 | 60.26% | ― | 25.96% | ― | |
51 Neutral | $1.33B | ― | -422.66% | ― | 49.29% | 44.52% | |
50 Neutral | $1.65B | ― | -70.58% | ― | 100.03% | 64.22% | |
49 Neutral | AU$2.49B | 4.37 | -64.25% | 2.83% | 36.51% | 13.14% | |
46 Neutral | $1.45B | ― | -9.32% | ― | 28.12% | -11.01% | |
39 Underperform | $1.53B | ― | -39.49% | ― | ― | -20.03% |
At the 2025 Annual Meeting of Stockholders held on June 18, Agios Pharmaceuticals’ stockholders approved an amendment to the 2023 Stock Incentive Plan, increasing the number of shares available for issuance by 2,500,000. Additionally, the stockholders elected two directors, approved executive compensation, and ratified the appointment of PricewaterhouseCoopers LLP as the independent auditor for the fiscal year, reflecting strong support for the company’s strategic direction.
The most recent analyst rating on (AGIO) stock is a Hold with a $56.00 price target. To see the full list of analyst forecasts on Agios Pharma stock, see the AGIO Stock Forecast page.